C2174005
Cilazapril impurity D
European Pharmacopoeia (EP) Reference Standard
Synonim(y):
(1S,9S)-9-{[(R)-1-Ethoxycarbonyl-3-phenylpropyl]amino}-10- oxo-octahydro-6H-pyridazino[1,2a][1,2]diazepine-1-carboxylic acid
Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
About This Item
Wzór empiryczny (zapis Hilla):
C22H31N3O5
Numer CAS:
Masa cząsteczkowa:
417.50
Kod UNSPSC:
41116107
NACRES:
NA.24
Polecane produkty
klasa czystości
pharmaceutical primary standard
rodzina API
cilazapril
producent / nazwa handlowa
EDQM
Zastosowanie
pharmaceutical (small molecule)
Format
neat
temp. przechowywania
2-8°C
Opis ogólny
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Zastosowanie
Cilazapril impurity D EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Opakowanie
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Inne uwagi
Sales restrictions may apply.
Ta strona może zawierać tekst przetłumaczony maszynowo.
produkt powiązany
Wybierz jedną z najnowszych wersji:
Certyfikaty analizy (CoA)
Lot/Batch Number
Przepraszamy, ale COA dla tego produktu nie jest aktualnie dostępny online.
Proszę o kontakt, jeśli potrzebna jest pomoc Obsługa Klienta
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
Mustafa Tuncer et al.
Advances in therapy, 25(2), 99-105 (2008-02-26)
P-wave dispersion (PWD) has been shown to be a non-invasive electrocardiographic predictor for development of atrial fibrillation (AF). Thus, it may be possible to decrease AF risk through improvement in PWD. Our objective was to compare the effects of cilazapril
Eduardo Cantoni Rosa et al.
Arquivos brasileiros de endocrinologia e metabologia, 52(1), 65-75 (2008-03-18)
Blood pressure (BP) and target organ responses to antihypertensive drugs are not well established in hypertensive obese patients. This study is aimed at evaluating the effects of obesity and adiposity distribution patterns on these responses. 49 hypertensive obese women were
Yan-Xing Zhang et al.
Internal medicine (Tokyo, Japan), 47(9), 867-875 (2008-05-03)
Reversible posterior encephalopathy syndrome (RPES) is a clinical entity characterized with headache, nausea, vomiting, seizures, consciousness disturbance, and frequently visual disorders associated with neuroradiological findings, predominantly white matter abnormalities of the parieto-occipital lobes. The central nervous system manifestations of systemic
Jicheng Lv et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 53(1), 26-32 (2008-10-22)
Recent studies have shown that both steroids and angiotensin-converting enzyme (ACE) inhibitors improve kidney survival and decrease proteinuria in patients with immunoglobulin A nephropathy. In this study, we aim to investigate whether the addition of steroids to ACE-inhibitor therapy produces
E Dervis et al.
Acta dermatovenerologica Alpina, Pannonica, et Adriatica, 19(3), 31-34 (2010-10-27)
A 54-year-old woman presented with angiomatous lesions located on the upper extremities and right cruris. Histopathological findings were typical of Kaposi's sarcoma (KS). She had had mild to moderate psoriasis since she was 25 years old. She had been using
Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.
Skontaktuj się z zespołem ds. pomocy technicznej